Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome

More on GLP-1 and incretin signalling

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• Cumulative non-HDL cholesterol is linked to CVD risk

  Journal of Diabetes and Metabolic Disorders · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Cardiovascular risk from metabolic burden weakens with age

  The Lancet Regional Health Western Pacific · 4 Oct 2026